chekt with dubs
kek
bet she has stamina
Paralyzed man with brain chip posts ‘first direct-thought’ tweet
https://www.rt.com/news/544428-tweet-thought-brain-implant/
A company that implants neural computer interfaces into the brain says a patient with a nervous system disease that left him motionless was able to share a post on social media by just thinking it.
A 62-year-old man in Australia diagnosed with amyotrophic lateral sclerosis (ALS) – a disease that causes paralysis – is now able to communicate thoughts with others with no muscle activity involved. On Thursday, he published a post on social media “using only direct thought,” the company that enabled him to do so, Synchron, announced.
“I created this tweet just by thinking it” – the tweet read, said to be posted by Philip O’Keefe to the account of Synchron CEO Thomas Oxley.
The ‘first direct-thought tweet’ was created wirelessly from O’Keefe’s brain, according to the company. Following progressive paralysis caused by ALS, the man had a brain computer interface called ‘Stentrode’ installed last year. The implant, “designed to enable patients to wirelessly control digital devices through thought,” was inserted via the jugular vein to avoid drilling into the skull.
https://twitter.com/tomoxl/status/1473809025254846467
“Now, I just think about where on the computer I want to click, and I can email, bank, shop, and now message the world via Twitter,” the company cited O’Keefe as saying – or thinking. According to him, the “astonishing” system takes practice, just like learning to ride a bike, “but once you’re rolling, it becomes natural.”
The man, despite debilitating paralysis, is now able to engage in independent activities and reconnect with the world, Synchron claims, adding that it plans to further develop its brain computer interface in an in-human study in the US next year.
Synchron Our story
https://synchron.com/about-us
Innovating an Industry
Since 2012, we have been developing a solution that avoids the need for open brain surgery by using a minimally-invasive procedure.
Quick facts about us
The device, the stentrode™, is 8mm in diameter and made from a flexible alloy called nitinol. It is inserted into Superior Sagittal Sinus in the brain via the jugular vein.
Initial grant funding was provided to a lab in the University of Melbourne by the U.S. Defense Advanced Research Projects Agency (DARPA) and Department of Defense (DoD).
In 2020, FDA awarded the stentrode™ the Breakthrough Device Designation. In 2021, Synchron became the first company to receive FDA approval for an IDE to conduct trials of a permanently implantable BCI.
Series B funding was led by Khosla Ventures, with total capital raised now of $70M, including support from the U.S. and Australian governments.
Synchron is headquartered in Brooklyn, New York, and has an office in Melbourne, Australia.
The Team
We’re a global team of scientists, innovators, and future-thinkers.
Tom Oxley CEO
Nick Opie CTO
Amos Meltzer CLO Chief Legal Officer
J Mocco Chief Medical Officer <←
Gary Castro VP Finance
Riki Banerjee VP RD
Edward Karst Senior Director of Clinical Regulatory
Chloe Brown Director of Marketing
Gil Rind Director of Advanced Technologies
Peter Yoo Director of Neuroscience <←
Darragh Mc Dermott Director of Hardware
Amanda Zwarenstein Director of Product 1
Partners
Khosla Ventures
Neuro Technology Investors
Metis Innovative
Published Work
https://synchron.com/research
International peer-reviewed scientific publications authored by scientists and engineers at Synchron.
Motor neuroprosthesis implanted with neurointerventional surgery improves capacity for activities of daily living tasks in severe paralysis: first in-human experience
Oxley TJ, et al. J NeuroIntervent Surg 2020;0:1–7. doi:10.1136/neurintsurg-2020-016862
https://jnis.bmj.com/content/13/2/102.info
Removing the need for invasive brain surgery: the potential of stent electrodes
Opie NL and Oxley TJ. Future Medicine. vol. 2(1), editorial.
https://www.futuremedicine.com/doi/abs/10.2217/bem-2019-0013?journalCode=bem
Neural Stimulation with an Endovascular Brain-Machine Interface
Opie NL, John SE, Gerboni G, Rind GS, Lovell TJ, Ronayne SM, et al. 9th International IEEE/EMBS Conference on Neural Engineering (NER), pp. 738-741.
https://ieeexplore.ieee.org/document/8717066
…much moar… 2016-2021
In the news
https://synchron.com/news
America's Greatest Disruptors: Medical Marvels
https://www.newsweek.com/2021/12/24/americas-greatest-disruptors-medical-marvels-1659061.html
Next Big Things in Tech 2021
https://www.fastcompany.com/next-big-things-in-tech
2022 Dr John Raftos AM Award Winner: Prof Nicholas Opie
https://nfmri.org.au/research-and-innovation/dr-john-raftos-medal/
THE BEST INVENTIONS OF 2021
https://time.com/collection/best-inventions-2021/
‘Our notion of privacy will be useless’: what happens if technology learns to read our minds?
https://amp.theguardian.com/technology/2021/nov/07/our-notion-of-privacy-will-be-useless-what-happens-if-technology-learns-to-read-our-minds
NIH backs Synchron Brain Computer Interface with $10M grant to launch first U.S. clinical trialPDF
https://drive.google.com/uc?export=download&id=1botWAtw3e4hXAZglpJm2up7S5b9EWGwJ
Ability to Conduct Human Trials Gives Synchron the Edge in BCI Market
https://www.mddionline.com/implants/ability-conduct-human-trials-gives-synchron-edge-bci-market
How a Small Neurotech Startup Beat Elon Musk’s Neuralink to Human Studies
https://futurism.com/neoscope/neurotech-startup-beat-elon-musk-neuralink-fda-approval
RELATED
Human brain chip pending FDA approval, Musk says
https://www.rt.com/usa/542505-musk-neuralink-human-testing/
Synchron
Syn Chron
Sin Time
Also has an office in Chinafornia
https://www.zoominfo.com/c/synchron/397959100
Description
Synchron, Inc. is a neurovascular bioelectronics medicine company developing bloodstream-enabled solutions for previously-untreatable nervous system conditions…. Read More
Headquarters:
1999 S Bascom Ave, Ste 707, Campbell, California, 95008, United States
Phone:
(917) 216-0774
Website:
https://www.synchronmed.com
Employees:
<25
Revenue:
<$5 Million
SIC Code 38,384
NAICS Code 339,339112
>Tom Oxley CEO
Thomas J Oxley, MD, PhD
https://www.mountsinai.org/profiles/thomas-j-oxley
Thomas J. Oxley, MD, PhD, is an instructor and Director of Innovation Strategy for the Department of Neurosurgery at the Mount Sinai Health System. As part of the Cerebrovascular Center, he specializes in vascular neurosurgery and interventional neurology, including the treatments of stroke, brain aneurysms, and vascular malformations. In his strategic role in the new Sinai BioDesign Center, he assists faculty members in the development of novel devices and technologies. The center already has over 20 projects in development and is currently seeking new concepts.
Dr. Oxley is the founder and CEO of Synchron, a neural interface technology company. The internationally acclaimed stentrode device can record brain activity from within a blood vessel. In the intended application of the technology, the user’s thoughts are captured, decoded and passed wirelessly through the skin to enable control of digital devices that enable movement and speech restoration to previously paralyzed patients. A human clinical trial is close to commencement.
Dr. Oxley completed his PhD in neural engineering at the University of Melbourne, then completed both internal medicine and neurology residencies, as well as a stroke fellowship, in Australia. He performed his endovascular neurosurgery fellowship alongside Dr. Kellner at Mount Sinai under the direction of Drs. Mocco, Berenstein, Fifi, and De Leacy.
Dr. Oxley was published as first author in Nature Biotechnology for his research on “Minimally Invasive Endovascular Stent-Electrode Array for High-Fidelity, Chronic Recordings of cortical neural activity.” He has also published 30 internationally peer-reviewed articles that have accumulated 2080 citations with an H Index of 10.
Clinical Focus
Amyotrophic Lateral Sclerosis
Aneurysm Coiling
Brain Aneurysm
Brain Tumors
Carotid Artery Stenosis
Carotid Stenting
Cavernous Malformations
Cerebral Vasospasm
Dural Arteriovenous Fistula (DAVF)
Endovascular Embolization
Facial Arteriovenous Malformations
Facial Vascular Malformations
Hemangioblastoma
Mechanical Thrombectomy
Spinal Vascular Malformations
Stroke
Subarachnoid Hemorrhage
Vascular Malformations
Venous Sinus Thrombosis
Research Topics
Amyotrophic Lateral Sclerosis, Biomechanics/Bioengineering, Electrophysiology, Epilepsy, MRI, Motor Control, Muscular Dystrophy, Neuromodulation, Neurophysiology, Rehabilitation, Spinal Cord, Stroke
Education
MD, Monash University
Residency
Albury Hospital
Residency, Neurology
Alfred Hospital
Residency, Neurology
Royal Melbourne Hosp
Fellowship, Stroke Fellowship
Royal Melbourne Hospital
Fellowship, Vascular Neurology
Mount Sinai Hospital
Publications
https://plu.mx/mtsinai/u/toxley
Industry Relationships
Physicians and scientists on the faculty of the Icahn School of Medicine at Mount Sinai often interact with pharmaceutical, device and biotechnology companies to improve patient care, develop new therapies and achieve scientific breakthroughs. In order to promote an ethical and transparent environment for conducting research, providing clinical care and teaching, Mount Sinai requires that salaried faculty inform the School of their relationships with such companies.
Below are financial relationships with industry reported by Dr. Oxley during 2020 and/or 2021. Please note that this information may differ from information posted on corporate sites due to timing or classification differences.
Company Founder:
Synchron, Inc
Consulting:
Synchron, Inc
Employment:
Synchron, Inc
Equity (Stock or stock options valued at greater than 5% ownership of a publicly traded company or equity of any value in a privately held company)
Synchron Inc
Industry-Sponsored Lectures: MSSM faculty occasionally give lectures at events sponsored by industry, but only if the events are free of any marketing purpose
Synchron, Inc
Other activities: Examples include, but are not limited to, committee participation, data safety monitoring board (DSMB) membership
Synchron, Inc
Scientific Advisory Board:
Synchron, Inc
Service on Board of Directors: Service in a fiduciary capacity, such as an officer or director, for the following companies:
Synchron, Inc
Mount Sinai's faculty policies relating to faculty collaboration with industry are posted on our website. Patients may wish to ask their physician about the activities they perform for companies.
>Straight from the south park episode.
Yep.
Thought about it long before South Park existed.
Also Johnny Mnemonic and other sci-fi of old (books)
https://youtu.be/lM_gxTns6_8
8 Minutes in to Godfather III
"The Pope, the Holy Father himself, has this very day blessed Michael Corleone; an' you think you know better than the Pope?"
Dominic Abbandando (Michael's PR Advisor, son of Genco) to reporters
http://www.thegodfathertrilogy.com/gf3/gf3quots.html
Godfather III 26:00 minutes in
https://www.thegatewaypundit.com/2021/12/predictable-young-father-got-joe-biden-repeat-go-brandon-now-getting-death-threats-angry-leftists/
Godfather III transcript
http://www.thegodfathertrilogy.com/gf3/transcript/gf3transcript.html